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European patients, and in subgroup analysis of prospective ran-
domized studies. There are few data about the impact of this
treatment on QoL.
From April 2010 to April 2011 we prospectively evaluated
skin-toxicity related QoL in 15 consecutive pts aged >70 yrs
treated with cetuximab for MCRC in our outpatient clinic. After
one month of cetuximab therapy skin toxicity was recorded using
the CTC NCI 3.0 version and QoL was evaluated using the Der-
matology Life Quality Index (DLQI) Italian version. Relation-
ship between cumulative skin toxicity scoring and QoL impact
was evaluated with linear regression testing and Anova testing.
Mean age was 74.5 yrs ± 4.5. Two were female pts and 13
male. No patients had previous history of skin illness. Rash and
desquamation were detected in all pts (9 G1 and 6 G2), xerosis in
13 pts (12 G1 and 1 G2), nail changes in 5 pts (all G1), hitching
in 7 pts (all G1). No skin toxicity >G2 was recorded. Global toxi-
city score was obtained adding single item scores. DLQI global
score showed a small effect of skin toxicity on QoL in 9 pts, a
moderate effect in 6 pts and a large effect in no patient. The most
affected headings were ‘symptoms and feelings’ and ‘daily activ-
ities’. Less important was the impact on ‘leisure’ and ‘personal
relationships’ and ‘work and study’. No relationship was found
between toxicity scoring and DLQI scoring.
Skin toxicity after one month of cetuximab therapy in this el-
derly group of pts was similar to that previously reported in no
age-selected population. The lack of severe toxicity may be due
to the short duration of therapy when data were recorded and also
to the use of prophylactic treatment with UV-filters and skin-
moisturizers. DLQI is probably less effective for QoL evaluation
in elderly people because it emphasizes some life aspects (work
and social relationships) less important in this group than in
younger people. Despite this, our data seem to confirm not only
the good toxicity profile of cetuximab in elderly people but also
its tolerable impact on QoL.
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Background. BM from CRC are rare (2-4%) and median sur-
vival (MS) is dismal (3 months), mainly due to late diagnosis,
extensive systemic disease, treatment refractoriness, cerebellar
involvement and poor performance status. Although brain imag-
ing is not routinely performed in metastatic CRC, better patients
(pts) survival will likely result in increased BM incidence.
Patients and methods. A retrospective analysis was per-
formed on CRC pts with BM treated at a single Institution, in or-
der to collect data about clinical features and outcome. Radiation
Therapy Oncology Group recursive partitioning analysis (RPA)
was used to assess prognosis.
Results. From January 2005 to April 2011, 26 consecutive
CRC pts with BM were treated at the National Cancer Institute of
Milan. All were diagnosed for neurologic symptoms. Median age
60 years (range 41-85), M/F:12/14, 13 (50%) solitary BM, 12
(46%) supratentorial, 7 (27%) cerebellar and 7 (27%) both, mean
diameter 27 mm. Twenty (77%) pts had progressive pulmonary
disease, 10 (38%) mediastinal involvement, 19 (73%) multiple
metastatic sites and only 4 (15%) isolated brain progression. Me-
dian time from primary diagnosis and from thoracic metastases to
BM was 3 years and 27 months, respectively. Six patients (23%)
were treated with surgery and adjuvant/salvage radiation: all had
single BM, with younger age and controlled/absent extracranial
disease; twenty (77%) pts received radiotherapy alone, either
stereotactic, whole brain or both. MS for the overall population
was 16.5 weeks; 6-month survival, 34%. MS according to treat-
ment: surgery plus adjuvant/salvage radiotherapy: 12.5 months;
radiotherapy alone: 6 weeks. MS according to RPA: class I, 52
weeks; class II, 28 weeks; class III 2 weeks.
Conclusions. Diagnosis of BM from CRC is often late and
prognosis is extremely poor. RPA III pts should be treated with
supportive care alone, while selected RPA I pts can benefit from
multimodality treatments. Brain imaging in plurimetastatic CRC
pts should be done starting 2 years after initial diagnosis of lung
metastases and in case of progressive thoracic disease.
E36 SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES
TO RESISTANCE TO EPIDERMALGROWTH FACTOR
RECEPTOR (EGFR) INHIBITORS IN COLORECTAL
CANCER MODELS
Nappi L.1, Rosa R.1, Damiano V.1, Formisano L.1,
Gelardi T.1, D’Amato C.1, Marciano R.1, De Maio A.P.1,
Ferrara R.1, Tortora G.2, Veneziani B.M.3, De Placido S.1,
Bianco R.1
1Dipartimento di Endocrinologia ed Oncologia Molecolare e
Clinica, Laboratori di Terapia Medica dei Tumori, Università
Federico II Napoli; 2Cattedra di Oncologia Medica, Università
di Verona; 3Dipartimento di Biologia e Patologia Cellulare e
Molecolare “L. Califano”, Università Federico II di Napoli
Background. Although EGFR targeted agents represent an ef-
fective strategy in the treatment of several cancer types, includ-
ing colorectal cancer (CRC), the clinical use of these agents is
significantly limited by intrinsic or acquired resistance. Alter-
ations in the ‘sphingolipid rheostat’, or the balance between the
proapoptotic molecule ceramide and the mitogenic factor sphin-
gosine-1-phosphate (S1P), due to overactivation of sphingosine
kinase 1 (SphK1), have been involved in the regulation of resis-
tance to both chemotherapeutics and targeted agents.
Experimental plan. Since some studies have described cross-
talks between SphK1 and EGFR-dependent signalling pathways,
we investigated the involvement of SphK1 in resistance to EGFR
inhibitors in CRC models.
Results. We used CRC cell models with both intrinsic or ac-
quired resistance to the anti-EGFR monoclonal antibody cetux-
imab. We found that SphK1 is overexpressed in CRC cells resis-
tant to EGFR inhibitors. Consistently with this data, higher doses
of N, N-dimethylsphingosine (DMS), a potent competitive in-
hibitor of SphK1, are needed to achieve complete enzyme satura-
tion and survival inhibition in resistant cells. Moreover, ceramide
induces apoptosis less efficiently in resistant than in sensitive
cells, consistently with the idea that increased SphK1 levels me-
diate S1P synthesis by ceramide in resistant cells. The contribu-
tion of SphK1 to the resistant phenotype was supported by the
demonstration that SphK1 inhibition by DMS or silencing via
siRNA in resistant cells restores sensitivity to anti-EGFR drugs,
whereas exogenous SphK1 overexpression in wild-type cells
confers resistance to these agents. Finally, treatment of resistant
CRC cells with fingolimod (FTY720), a S1P receptor inhibitor,
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resulted in re-sensitization to cetuximab even in presence of
KRAS mutation. We are now investigating the correlation be-
tween SphK1 expression in tissue samples derived from CRC pa-
tients with KRAS mutations and response to cetuximab.
Conclusions. Our data could contribute to clarify the role of
SphK1 in the onset of resistance to EGFR inhibitors and they
may suggest SphK1 inhibition as a part of novel targeting strate-
gies potentially effective also in resistant cancer patients.
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Introduction. The use of bevacizumab, anti-VEGF monoclon-
al antibody, in combination with regimens based on 5FU/LV (or
capecitabine) ± irinotecan or oxaliplatin, considerably improved
prognosis of patients with metastatic colorectal cancer (mCRC).
However, potential adverse events such as hypertension, protein-
uria, bleeding, gastrointestinal perforation and thrombosis should
be considered especially in elderly patients. Aim of our study was
to assess bevacizumab-related adverse events and their influence
on quality of life in two groups of patients with mCRC.
Patients and methods. From January 2008 to June 2010 we
studied 59 patients with mCRC, receiving first-line chemothera-
py plus bevacizumab (5 mg/kg every 2 weeks), divided in two
groups, the first of 28 patients aged ≤70 years (range 35-70;
mean 58.4 years) and the second of 31 patients >70 years (range
71-79; mean 72.7 years). Patients with impaired renal function
and/or proteinuria ≥0.5 g/day were excluded. Adverse events
were defined according to the National Cancer Institute Common
Terminology Criteria (NCI-CTCAE v3.0.) Quality of life was as-
sessed with FACT-C, EORTC-C30 and CR38 questionnaires. Pa-
tients were evaluated at baseline, at each cycle of therapy, three
and six months after the end of chemotherapy.
Results. Any grade hypertension occurred in 7 (25%) patients
≤70 years and in 9 (29%) older patients. Grade 3 hypertension,
requiring the initiation or a change of antihypertensive therapy,
was observed in 3 (10.7%) patients ≤70 years and in 4 (12.9%)
patients >70 years. Proteinuria occurred in 8 (28.6%) patients
≤70 years and in 9 (29%) older patients. Grade 4 hypertension
(hypertensive crisis) and/or grade 4 proteinuria (nephrotic syn-
drome) was not seen. The FACT-C and EORTC questionnaires
showed that bevacizumab-related side effects had no impact on
quality of life.
Conclusion. In our study combination therapy with beva-
cizumab was well tolerated with a generally manageable safety
profile in all patients. Bevacizumab-related adverse events such
as hypertension and proteinuria, while noting more prevalent in
patients aged >70 years, had no significant effects on quality of
life.
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Background. Bevacizumab, a humanized monoclonal anti-
body inhibiting VEGF tumour angiogenetic activity, was ap-
proved, in combination with chemotherapy, for treating many
types of advanced cancer. Because of the important role of VEGF
in vascular function and physiological angiogenesis its inhibition
by bevacizumab has been noted to cause serious adverse events,
including bleeding, thromboembolic events, bowel perforation
and neutropenia.
The aim of this observational retrospective study was to evalu-
ate the safety and the toxicity profile of bevacizumab in addition
to several chemotherapeutic regimens in advanced cancer.
Materials and methods. From January 2006 to April 2011, 89
patients with metastatic cancer (84 colorectal, 3 renal, 1 breast, 1
lung) were treated with bevacizumab, in addition to different
chemotherapeutic regimens (74 patients CPT11+5FUic, 6 FOL-
FOX4, 4 degramont, 1 paclitaxel, 1 carboplatin-paclitaxel, 3 in-
terferon) in Medical Oncology Department of Azienda Ospe-
daliera di Desio e Vimercate. Eighty-five (96%) patients received
bevacizumab as first-line chemotherapy and 4 (4%) as second-
line. The G3-G4 toxicities were recorded according to WHO
classification system. Results are based on descriptive analysis of
the first toxicity event.
Results. Overall G3 and G4 toxicities were reported in 24 pa-
tients (27%). Adverse events leading to treatment discontinuation
were recorded in 7 patients (7.8%). One death occurred, due to a
thromboembolic event (1.1% fatal event).
Type of ADR No. G3-G4 ADR (%) Treatment
discontinuation
(%)
Hypertension 13 (14.60%) 1 (1.1%)
Bleeding 3 (3.40%) 1 (1.1%)
Thromboembolic events 2 (2.20%) 3 (3.4%)
Other events GI disorders 3 (3.4%) 2 (2.2%)
Myelotoxicities 2 (2.2%)
Cardiac disorders 1 (1.1%)
Conclusions. According to our experience, bevacizumab plus
chemotherapy seems to be a well tolerated treatment in clinical
practice, and its safety profile in addition to chemotherapy ap-
pears consistent with those reported by other experiences. Hyper-
tension, the most common adverse event, was well manageable
and leaded to treatment discontinuation only in one case. Data
suggest particular attention to thromboembolic events, being the
most frequent cause of treatment discontinuation.
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